Quarterly Investor Briefing

October 2025

Vitrafy Life Sciences Limited (ASX: VFY)
ACN 622 720 254

vitrafy.com

Quarterly Company Update

Across Quarter 1 ("Q1") Financial Year 2026 ("FY26"), Vitrafy continued to build out the platform for sustainable growth with progress across all areas of the business.

VCU2 Delivered

Successfully delivered the first production unit of Vitrafy's second generation cryopreservation unit ("**VCU2**").

Board Renewal

Board and Executive renewal commenced to support the next phase of growth and commercialisation.

U.S Expansion

U.S. footprint expansion with key appointments to support Sales and Commercial Operations ahead of the planned market launch.

Commercial Milestone

Commercialisation milestones achieved in Aquaculture and Blood Platelets with existing strategic partners, Huon Aquaculture and the USAISR.

Strong Financial Position

A$25.8m in cash and short-term assets providing run way well into CY2027

Scale Up Underway

Preparing for scaled production of VCU2 devices ahead of go-to-market launch and anticipated commercialisation activity.

vitrafy LIFE SCIENCES

Product Development

During Q1, Vitrafy achieved a major milestone with the successful delivery of the first production unit of VCU2.

Vitrafy's VCU2 Produced in Q1

- Delivery in-line with expectations and ahead of market launch later this calendar year.
- >12 months effort and significant resource investment to enable commercialisation.
- Factory acceptance testing now underway.
- Preparing the path for scale manufacturing of the devices for deployment with customers.

vitrafy LIFE SCIENCES

Product Developments

Vitrafy has designed a commercial-ready product with a competitive edge.

Hardware VCU2

- Leverage learnings from VCU1 to have a scalable product in market
- Increased performance and reliability with expanded functionality
- Unlock global market opportunities through worldwide power compatibility
- Enable scaled manufacturing capability domestically and internationally
- Integrated LifeChain software

Regulation:
FDA 510(k) Exempt – USA

Software LifeChain

- Scalable infrastructure and architecture to capture volumes of data and increase performance
- VCU2 system control, data insights and remote access
- Workflow connectivity – end to end through device integrations (IoT)
- Software development according to regulatory compliance standards and cyber security expectations

Regulation:
21 CFR Part 11
IEC 62305 (Software as a Medical Device)

Board & Executive Renewal

Board and Executive renewal underway to support the next phase of growth and commercialisation.

Incoming Chair of VFY.ASX: Dr. Leigh Farrell

- **1 September 2025**: Successful CEO transition to Brent Owens.
- **16 October 2025**: Appointment of **Dr. Leigh Farrell** as an independent, Non-Executive Director.
- **20 November 2025**: Retirement of Chair **Ms. Sonia Petering** & NED **Associate Prof. John McBain**.
- **21 November 2025**: Dr. Farrell to takeover as Chair of Vitrafy Life Sciences[1] .

1. Dr. Leigh Farrell election subject approval by Shareholders at the AGM

Commercial Strategy

Vitrafy is implementing a managed service model that requires a seamless customer experience from lead generation to customer support and that will be charged on a monthly, recurring fee basis.

Managed Service Business Model

HARDWARE | BASIC SOFTWARE | SUPPORT & SERVICE

Lead Generation & Conversion → On Boarding Implementation → Customer Success & Support

vitrafy LIFE SCIENCES

U.S. Expansion

Commercialisation activities and preparation core operational focus in the lead up to launch of VCU2.

- Q1 efforts focussed on building out Vitrafy's market facing capability and mapping customer success.
- Key business leads secured in the U.S. for Commercial Operations and Sales.
- Sales and Marketing + Commercial Operations = **Vitrafy's market face**.
- Early education and engagement with target market via conference attendance generating customer interest.

vitrafy
LIFE SCIENCES

Commercialisation Update - Aquaculture

Strong scale up in cryopreservation with Huon resulted in a record quantity of salmon eggs fertilised via milt cryopreserved via Vitrafy's technology.



- Successfully completed the spring fertilisation period with results comparable to fresh fertilisation
- ~2 million eggs fertilised up from ~500,000 last calendar year
- Milestone reflects the improved fertilisation yield achievable through Vitrafy's technology and the growing contribution of assisted reproduction to annual breeding volumes

vitrafy
LIFE SCIENCES

Commercialisation Update – U.S. Military

Further deepening of relationship with the U.S. Military with operational and marketing progress.

- Vitrafy commenced the second phase of the platelet study with the U.S. military.
- The study will result in a doubling of the quantity of commercial scale platelet products.
- Vitrafy and the USAISR will co-present the Phase 1 study results at the Association for the Advancement of Blood & Biotherapies 2025 Annual Meeting in San Diego, USA in late October.

Financial Update

Vitrafy ended Q1 with expenditure tracking in-line with expectations.



- Cash costs proceed in line with expectation:
  - Net cash burn $3.7m for the quarter.
  - Cash costs ~$4.2m for the quarter compared to ~$4.7m for prior quarter

- Income of ~$0.5m received associated with aquaculture activities and interest income from term deposits.

vitrafy LIFE SCIENCES

Financial Update

Vitrafy ended the quarter with a strong cash balance and clear funding pathway.



- Cash and short-term assets at the end of the quarter were A$25.8m.
- Industry Growth Program grant funding balance of ~A$2.4m due over the next 12 months.
- Excluding any assumptions surrounding revenue, Vitrafy has cash runway well into calendar year 2027.

vitrafy LIFE SCIENCES

Summary of Execution

With Vitrafy approaching its first anniversary as an ASX listed business, the Company has achieved significant milestones.

In the first 12 months since listing the Company has executed:

- Successful delivery of VCU2 project and LifeChain Software Platform
- Build out of U.S. footprint
- Marketing and brand development establishment
- Progress and execution with existing partners

Outlook

Vitrafy remains focussed on executing commercialisation in our target market of North America.

- **The next 9 months for the Company will be focussed on**:
    - Converting existing customer pipeline opportunities;
    - Securing medical device registration to expand the addressable market in the U.S.; and
    - Building a supply of devices in advance of market demand for immediately addressable markets

vitrafy LIFE SCIENCES